Picton Mahoney Asset Management Buys New Shares in Translational Development Acquisition Corp. (NASDAQ:TDACU)

Picton Mahoney Asset Management purchased a new stake in Translational Development Acquisition Corp. (NASDAQ:TDACUFree Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 250,000 shares of the company’s stock, valued at approximately $4,610,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Schechter Investment Advisors LLC bought a new stake in Translational Development Acquisition in the 4th quarter valued at $2,778,000. Wealthspring Capital LLC bought a new stake in Translational Development Acquisition in the 4th quarter valued at $1,095,000. MMCAP International Inc. SPC bought a new stake in Translational Development Acquisition in the 4th quarter valued at $6,454,000. Wolverine Asset Management LLC bought a new stake in Translational Development Acquisition in the 4th quarter valued at $5,716,000. Finally, Calamos Advisors LLC bought a new stake in shares of Translational Development Acquisition in the 4th quarter worth about $6,915,000.

Translational Development Acquisition Stock Performance

Translational Development Acquisition stock opened at $10.14 on Friday. The business has a 50-day simple moving average of $10.08. Translational Development Acquisition Corp. has a twelve month low of $10.00 and a twelve month high of $10.30.

Translational Development Acquisition Company Profile

(Free Report)

Trident Acquisitions Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more target businesses primarily in the oil and gas or other natural resource sector.

See Also

Institutional Ownership by Quarter for Translational Development Acquisition (NASDAQ:TDACU)

Receive News & Ratings for Translational Development Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translational Development Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.